These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 22257652)

  • 1. Target therapy in elderly breast cancer patients.
    Carli P; Turchet E; Quitadamo D; Spada A; Miolo G; Lamaj E; Spazzapan S; Di Lauro V; Dolcetti R; Veronesi A; Crivellari D
    Crit Rev Oncol Hematol; 2012 Sep; 83(3):422-31. PubMed ID: 22257652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
    Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
    Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ErbB family receptor inhibitors as therapeutic agents in breast cancer: current status and future clinical perspective.
    Saxena R; Dwivedi A
    Med Res Rev; 2012 Jan; 32(1):166-215. PubMed ID: 22183797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological therapy of breast cancer: recent clinical applications.
    Baar J
    Curr Opin Investig Drugs; 2007 Dec; 8(12):987-95. PubMed ID: 18058569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer?
    Constantinidou A; Smith I
    Breast; 2011 Oct; 20 Suppl 3():S158-61. PubMed ID: 22015286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Novel target therapies used in breast cancer management].
    Semiglazova TIu; Semiglazov VV; Filatova LV; Gershanovich ML; Chudenko VA; Latipova DKh; Luk'ianchikova VS; Dashian GA; Paltuev RM
    Vopr Onkol; 2011; 57(5):592-600. PubMed ID: 22238928
    [No Abstract]   [Full Text] [Related]  

  • 7. The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2.
    Prat A; Baselga J
    Nat Clin Pract Oncol; 2008 Sep; 5(9):531-42. PubMed ID: 18607391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer.
    Cameron DA; Stein S
    Nat Clin Pract Oncol; 2008 Sep; 5(9):512-20. PubMed ID: 18594499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progression and treatment of HER2-positive breast cancer.
    Davoli A; Hocevar BA; Brown TL
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER2 as a target for breast cancer therapy.
    Tagliabue E; Balsari A; Campiglio M; Pupa SM
    Expert Opin Biol Ther; 2010 May; 10(5):711-24. PubMed ID: 20214497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lapatinib moves forward in inflammatory and early HER2-positive breast cancer trials.
    Tuma RS
    J Natl Cancer Inst; 2007 Mar; 99(5):348-9. PubMed ID: 17341725
    [No Abstract]   [Full Text] [Related]  

  • 12. Lapatinib: new directions in HER2 directed therapy for early stage breast cancer.
    Jo Chien A; Rugo HS
    Cancer Treat Res; 2009; 151():197-215. PubMed ID: 19593514
    [No Abstract]   [Full Text] [Related]  

  • 13. Novel cytotoxic backbones and targeted therapies: recent data and ongoing clinical trials.
    Moulder SL
    Clin Breast Cancer; 2010 Sep; 10 Suppl 2():S30-40. PubMed ID: 20805063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer.
    Tevaarwerk AJ; Kolesar JM
    Clin Ther; 2009; 31 Pt 2():2332-48. PubMed ID: 20110044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blockade of the HER family of receptors in the treatment of HER2-positive metastatic breast cancer.
    Sachdev JC; Jahanzeb M
    Clin Breast Cancer; 2012 Feb; 12(1):19-29. PubMed ID: 21903480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patients with anti-HER2 responsive disease: definition and adjuvant therapies.
    Burstein HJ
    Breast; 2011 Oct; 20 Suppl 3():S132-4. PubMed ID: 22015280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The use of targeted therapies in oncology and their impact in the design of clinical trials: epidermal growth factor receptors 1 and 2 as a paradigm].
    Dalmases A; Rojo F; Rovira A; Albanell J
    Med Clin (Barc); 2013 Aug; 141(4):176-80. PubMed ID: 23809407
    [No Abstract]   [Full Text] [Related]  

  • 18. Optimizing chemotherapy-free survival for the ER/HER2-positive metastatic breast cancer patient.
    Glück S; Arteaga CL; Osborne CK
    Clin Cancer Res; 2011 Sep; 17(17):5559-61. PubMed ID: 21764887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2-) breast cancers?
    Zardavas D; Fumagalli D; Loi S
    Curr Opin Oncol; 2012 Nov; 24(6):623-34. PubMed ID: 22960556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lapatinib in breast cancer: clinical experiences and future perspectives.
    Giampaglia M; Chiuri VE; Tinelli A; De Laurentiis M; Silvestris N; Lorusso V
    Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S72-9. PubMed ID: 21129615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.